Royal Bank Of Canada Cuts Alkermes (NASDAQ:ALKS) Price Target to $45.00

Alkermes (NASDAQ:ALKS) had its target price trimmed by Royal Bank Of Canada from $47.00 to $45.00 in a research report report published on Thursday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other research analysts have also recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Alkermes in a report on Monday, December 29th. HC Wainwright restated a “neutral” rating and issued a $43.00 price target on shares of Alkermes in a research note on Thursday. Wells Fargo & Company reduced their price target on Alkermes from $42.00 to $37.00 and set an “overweight” rating for the company in a report on Thursday, November 13th. Wall Street Zen lowered Alkermes from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 9th. Finally, Zacks Research cut Alkermes from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Alkermes currently has a consensus rating of “Moderate Buy” and an average price target of $44.07.

Alkermes Trading Down 2.1%

Shares of ALKS stock opened at $30.10 on Thursday. Alkermes has a twelve month low of $25.17 and a twelve month high of $36.32. The stock has a market cap of $5.02 billion, a P/E ratio of 21.05 and a beta of 0.49. The stock has a 50 day moving average of $31.54 and a 200 day moving average of $30.22.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). The firm had revenue of $384.55 million for the quarter, compared to analyst estimates of $380.44 million. Alkermes had a return on equity of 14.91% and a net margin of 16.37%.Alkermes’s revenue for the quarter was down 10.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.05 EPS. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. On average, research analysts predict that Alkermes will post 1.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $33.93, for a total transaction of $305,370.00. Following the completion of the sale, the executive vice president directly owned 57,740 shares in the company, valued at approximately $1,959,118.20. The trade was a 13.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Shane Cooke sold 61,200 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $34.57, for a total value of $2,115,684.00. Following the completion of the transaction, the director directly owned 103,744 shares of the company’s stock, valued at approximately $3,586,430.08. This represents a 37.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 148,148 shares of company stock worth $5,028,378 over the last ninety days. Corporate insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Alkermes

Several hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada raised its holdings in Alkermes by 117.2% in the 1st quarter. Royal Bank of Canada now owns 275,526 shares of the company’s stock valued at $9,098,000 after acquiring an additional 148,696 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alkermes in the first quarter valued at approximately $213,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Alkermes by 4.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company’s stock valued at $15,927,000 after purchasing an additional 20,091 shares in the last quarter. State of New Jersey Common Pension Fund D increased its holdings in shares of Alkermes by 15.1% in the second quarter. State of New Jersey Common Pension Fund D now owns 62,677 shares of the company’s stock valued at $1,793,000 after purchasing an additional 8,214 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in Alkermes by 1.3% during the second quarter. Envestnet Asset Management Inc. now owns 43,658 shares of the company’s stock worth $1,249,000 after buying an additional 551 shares in the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

More Alkermes News

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Analyst optimism — Wells Fargo raised its price target to $43 and kept an overweight stance, signaling bullish analyst conviction that shares have meaningful upside. Wells Fargo raises price target to $43
• Positive Sentiment: RBC still rates ALKS “outperform” and keeps a high price target ($45 after a small cut), indicating continued buy-side support from some sell-side analysts. RBC maintains outperform, lowers PT to $45
• Neutral Sentiment: CEO succession announced — Alkermes disclosed a leadership transition plan; such changes create short-term uncertainty but may be neutral-to-positive over time depending on execution. Alkermes announces CEO succession plan
• Neutral Sentiment: Revenue roughly in line/beat estimates while EPS missed — top-line results were not the primary problem; profitability and EPS dynamics drove the negative reaction. See earnings highlights and call transcript for detail. Q4 2025 earnings highlights
• Negative Sentiment: Earnings miss and downbeat near-term outlook — reported EPS (~$0.29) missed the ~$0.43 consensus and management set FY2026 EPS guidance in negative territory, undercutting the bull case and spurring the sell-off. Shares down after earnings miss
• Negative Sentiment: Market reaction — shares declined sharply on the news and trading volume picked up, reflecting short-term repositioning by investors. Coverage pieces and call transcripts detail investor pushback. ALKS down despite mixed results, leadership change
• Neutral Sentiment: Short-interest reporting in feeds shows inconclusive/zeroed data for February (no actionable signal from that dataset). Short interest note

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.